Article
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.
Molecular cancer - 5 Aug 2023
Zhang Linlin, Wang Liuchun, Wang Jingya, Chen Jinliang, Meng Zhaoting, Liu Zhujun, Jiang Xiangli, Wang Xinyue, Huang Chun, Chen Peng, Liang Yan, Jiang Richeng, Wang Jing, Zhong Diansheng, Shang Yanhong, Zhang Yan, Zhang Cuiying, Huang Dingzhi
Abstract excerpt
BACKGROUND: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study aimed to examine anlotinib plus icotinib as a first-line treatment option for advanced NSCLC carrying EGFR mutation with or without concurrent mutations. METHODS: This phase 2, single-arm, multicenter trial (ClinicalTrials.gov NCT03736837) was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.